Evidence map›Paper›PMID 26888022›Full record

ArticleHaematologica2016

Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study.

Sung-Eun Lee, Soo Young Choi, Hye-Young Song, Soo-Hyun Kim, Mi-Yeon Choi, Joon Seong Park, Hyeoung-Joon Kim, Sung-Hyun Kim, Dae Young Zang, Sukjoong Oh and 11 more

2 registry-linked trialsOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 79 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed, 2 pooled it
13.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01564836 naunknown statusnot on this map

A Multi-center Study of the Discontinuation of Imatinib in Adult Patients With Ph+ CML in CP Who Have a Complete Molecular Response to Imatinib

TypeinterventionalSponsorSeoul St. Mary's HospitalRan2010Enrolled50ConditionsChronic Myeloid Leukemia, Imatinib, Complete Molecular ResponseArmsImatinib treatment discontinuing
NCT03131986 unknown statusnot on this mapstarted 2017, after this paper: background citation

Cessation of Tyrosine Kinase Inhibitors in Patients With Chronic-phase Chronic Myelogenous Leukaemia Who Achieve Stable Deep Molecular Response

TypeobservationalSponsorThe University of Hong KongRan2017 to 2019Enrolled30ConditionsLeukemia, Myelogenous, Chronic Phase
3 · Its place in the literature

Who cites it

79 citing papers in PubMed, 2 syntheses or guidelines pooled it, 163 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Article
  16. Observational
  17. Article
  18. Review
  19. Article
  20. Article

19 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 14 institutions in 1 country.

Sung-Eun LeeDepartment of Hematology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.
Soo Young ChoiDepartment of Hematology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.
Hye-Young SongDepartment of Hematology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.
Soo-Hyun KimDepartment of Hematology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.
Mi-Yeon ChoiDepartment of Hematology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.
Joon Seong ParkDepartment of Hematology-Oncology, Ajou University School of Medicine, Suwon, Korea.
Hyeoung-Joon KimDepartment of Hematology-Oncology, Chonnam National University Hwasun, Hospital, Busan, Korea.
Sung-Hyun KimDepartment of Internal Medicine, Dong-A University College of Medicine, Busan, Korea.
Dae Young ZangDepartment of Internal Medicine, Hallym University College of Medicine, Anyang, Korea.
Sukjoong OhDivision of Hematology-Oncology, Department of Internal Medicine, Kangbuk Samsung Hospital, School of Medicine, Sungkyunkwan University, Seoul, Korea.
Hawk KimDivision of Hematology and Cellular Therapy, Ulsan University Hospital, University of Ulsan College of Medicine, Daegu, Korea.
Young Rok DoDivision of Hematology-Oncology, School of Medicine, Keimyung University, Daegu, Korea.
Jae-Yong KwakDivision of Hematology-Oncology, Chonbuk National University Medical School, Jeonju, Korea.
Jeong-A KimDepartment of Hematology, St. Vincent's Hospital, The Catholic University of Korea, Suwon, Korea.
Dae-Young KimDepartment of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Yeung-Chul MunDepartment of Hematology, School of Medicine, Ewha Womans University, Seoul, Korea.
Won Sik LeeDepartment of Internal Medicine, Inje University College of Medicine, Inje University Busan Paik Hospital, Ilsan, Korea.
Myung Hee ChangDepartment of Hematology-Oncology, National Health Insurance Service Ilsan Hospital, Ilsan, Korea.
Jinny ParkDepartment of Hematology, Gachon University Gil Hospital, Incheon, Korea.
Ji Hyun KwonDepartment of Hematology-Oncology, Chungbuk National University Hospital, Cheongju, Korea.
Dong-Wook KimDepartment of Hematology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea Catholic Leukemia Research Institute, The Catholic University of Korea, Seoul, Korea dwkim@catholic.ac.kr.
The Catholic University of Korea Seoul St. Mary's Hospital · KRAjou University · KRCatholic University of Korea · KRUniversity of Ulsan · KRChungbuk National University Hospital · KREwha Womans University · KRHallym University · KRInje University Busan Paik Hospital · KRJeonbuk National University · KRKeimyung University · KRNational Health Insurance Service Ilsan Hospital · KRSungkyunkwan University · KRThe Catholic University of Korea St. Vincent's Hospital · KRUlsan College · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of the Korean Imatinib Discontinuation Study was to identify predictors for safe and successful imatinib discontinuation. A total of 90 patients with a follow-up of ≥12 months were analyzed. After a median follow-up of 26.6 months after imatinib discontinuation, 37 patients lost the major molecular response. The probability of sustained major molecular response at 12 months and 24 months was 62.2% and 58.5%, respectively. All 37 patients who lost major molecular response were retreated with imatinib therapy for a median of 16.9 months, and all achieved major molecular response again at a median of 3.9 months after resuming imatinib therapy. We observed newly developed or worsened musculoskeletal pain and pruritus in 27 (30%) patients after imatinib discontinuation. Imatinib withdrawal syndrome was associated with a higher probability of sustained major molecular response (P=0.003) and showed a trend for a longer time to major molecular response loss (P=0.098). Positivity (defined as ≥ 17 positive chambers) of digital polymerase chain reaction at screening and longer imatinib duration before imatinib discontinuation were associated with a higher probability of sustained major molecular response. Our data demonstrated that the occurrence of imatinib withdrawal syndrome after imatinib discontinuation and longer duration of imatinib were associated with a lower rate of molecular relapse. In addition, minimal residual leukemia measured by digital polymerase chain reaction had a trend for a higher molecular relapse. (Trial registered at ClinicalTrials.gov: NCT01564836).

Indexed as

AdultAgedAged, 80 and overAntineoplastic AgentsFemaleFollow-Up StudiesFusion Proteins, bcr-ablHumansImatinib MesylateLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMaleMiddle AgedNeoplasm, ResidualPolymerase Chain ReactionPrognosisProtein Kinase InhibitorsAntineoplastic AgentsFusion Proteins, bcr-ablImatinib MesylateProtein Kinase Inhibitors

Identifiers

PMID26888022
PMCPMC5013960
OpenAlexW2278657325

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.